<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34779076</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>e13035</StartPage><MedlinePgn>e13035</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13035</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.13035</ELocationID><Abstract><AbstractText>Although the molecular mechanisms underlying amyotrophic lateral sclerosis (ALS) are not yet fully understood, several studies report alterations in tau phosphorylation in both sporadic and familial ALS. Recently, we have demonstrated that phosphorylated tau at S396 (pTau-S396) is mislocalized to synapses in ALS motor cortex (mCTX) and contributes to mitochondrial dysfunction. Here, we demonstrate that while there was no overall increase in total tau, pTau-S396, and pTau-S404 in ALS post-mortem mCTX, total tau and pTau-S396 were increased in C9ORF72-ALS. Additionally, there was a significant decrease in pTau-T181 in ALS mCTX compared controls. Furthermore, we leveraged the ALS Knowledge Portal and Project MinE data sets and identified ALS-specific genetic variants across MAPT, the gene encoding tau. Lastly, assessment of cerebrospinal fluid (CSF) samples revealed a significant increase in total tau levels in bulbar-onset ALS together with a decrease in CSF pTau-T181:tau ratio in all ALS samples, as reported previously. While increases in CSF tau levels correlated with a faster disease progression as measured by the revised ALS functional rating scale (ALSFRS-R), decreases in CSF pTau-T181:tau ratio correlated with a slower disease progression, suggesting that CSF total tau and pTau-T181 ratio may serve as biomarkers of disease in ALS. Our findings highlight the potential role of pTau-T181 in ALS, as decreases in CSF pTau-T181:tau ratio may reflect the significant decrease in pTau-T181 in post-mortem mCTX. Taken together, these results indicate that tau phosphorylation is altered in ALS post-mortem mCTX as well as in CSF and, importantly, the newly described pathogenic or likely pathogenic variants identified in MAPT in this study are adjacent to T181 and S396 phosphorylation sites further highlighting the potential role of these tau functional domains in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrozziello</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral</LastName><ForeName>Ana C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-7316-3295</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Sali M K</ForeName><Initials>SMK</Initials><AffiliationInfo><Affiliation>Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trombetta</LastName><ForeName>Bianca A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivis&#xe4;kk</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Alexandra N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordt</LastName><ForeName>Evan A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Lurie Center for Autism, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Spencer E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dooley</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Commins</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connors</LastName><ForeName>Theresa R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakley</LastName><ForeName>Derek H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosal</LastName><ForeName>Anubrata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez-Isla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spires-Jones</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, UK Dementia Research Institute, University of Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadri-Vakili</LastName><ForeName>Ghazaleh</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3435-3544</Identifier><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="Y">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList><CoiStatement>T.G.I. serves as member of a Lilly Monitoring Committee (DMC). B.T.H. is a member of Novartis, Dewpoint, and Cell Signaling Scientific Advisory Board (SAB), and of Biogen DMC, and acts as consultant for US DoJ, Takeda, Virgil, W20, and Seer; he receives grants from Abbvie, F prime, NIH, Tau consortium, Cure Alzheimer's fund, Brightfocus, and JPB foundations. S.E.A. has received honoraria and/or travel expenses for lectures from Abbvie, Eisai, and Biogen and has served on SAB of Cortexyme and vTv, and as consultant for Athira, Cassava, Cognito Therapeutics, EIP Pharma and Orthogonal Neuroscience, and has received research grant support from NIH, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Abbvie, Amylyx, EIP Pharma, Merck, Janssen/Johnson &amp; Johnson, Novartis, and vTv. T.S.J. is on the scientific advisory board of Cognition Therapeutics and receives collaborative grant funding from European Research Council, UK Dementia Research Institute, and Autifony. M.E.C. acts as consultant for Aclipse, Mt Pharma, Immunity Pharma Ltd., Orion, Anelixis, Cytokinetics, Biohaven, Wave, Takeda, Avexis, Revelasio, Pontifax, Biogen, Denali, Helixsmith, Sunovian, Disarm, ALS Pharma, RRD, Transposon, and Quralis, and as DSBM Chair for Lilly. J.D.B. has received personal fees from Biogen, Clene Nanomedicine, and MT Pharma Holdings of America, and grant support from Alexion, Biogen, MT Pharma of America, Anelixis Therapeutics, Brainstorm Cell Therapeutics, Genentech, nQ Medical, NINDS, Muscular Dystrophy Association, ALS One, Amylyx Therapeutics, ALS Association, and ALS Finding a Cure. G.S&#x2010;V. is a consultant for MarvelBiome. None of these had any influence over the current paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34779076</ArticleId><ArticleId IdType="pmc">PMC8877756</ArticleId><ArticleId IdType="doi">10.1111/bpa.13035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH Jr, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni&#x2010;Tsuchida E, Ma XR, Gitler AD. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020;108(5):822&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Wate R, Kaneko S, Ito H, Oki M, Tsuge A, et al. An autopsy case of sporadic amyotrophic lateral sclerosis associated with the I113T SOD1 mutation. Neuropathology. 2014;34:58&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23773010</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R, Toyoshima Y, Tada M, Tanaka H, Shimizu H, Shiga A, et al. Globular glial mixed four repeat tau and TDP&#x2010;43 proteinopathy with motor neuron disease and frontotemporal dementia. Brain Pathol. 2016;26:82&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029069</ArticleId><ArticleId IdType="pubmed">25787090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodakuntla S, Jijumon AS, Villablanca C, Gonzalez&#x2010;Billault C, Janke C, et al. Microtubule&#x2010;associated proteins: structuring the cytoskeleton. Trends Cell Biol. 2019;29:804&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">31416684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener. 2009;4:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663562</ArticleId><ArticleId IdType="pubmed">19284597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe MS. The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo). 2012;2012:796024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820460</ArticleId><ArticleId IdType="pubmed">24278740</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12:609&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23684085</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirscoveanu DFV, Pirici I, Tudorica V, Balseanu TA, Albu VC, Bondari S, et al. Tau protein in neurodegenerative diseases&#x2014;a review. Rom J Morphol Embryol. 2017;58:1141&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29556602</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs B, Mueller RL, Morfini G, Brady ST, Kanaan NM. Tau and axonal transport misregulation in tauopathies. Adv Exp Med Biol. 2019;1184:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099581</ArticleId><ArticleId IdType="pubmed">32096030</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Halliday G, Nisbet RM. Molecular pathogenesis of the tauopathies. Annu Rev Pathol. 2019;14:239&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">30355155</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Sideris DI, Carroll E, Rotariu S, Salomonsson S, Tzioras M, et al. Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol. 2018;135:213&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaki T, Ito H, Komure O, Kamada M, Nakamura M, Wate R, et al. Multiple proteinopathies in familial ALS cases with optineurin mutations. J Neuropathol Exp Neurol. 2018;77:128&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29272468</ArticleId></ArticleIdList></Reference><Reference><Citation>Moszczynski AJ, Hintermayer MA, Strong MJ. Phosphorylation of threonine 175 tau in the induction of tau pathology in amyotrophic lateral sclerosis&#x2010;frontotemporal spectrum disorder (ALS&#x2010;FTSD). A review. Front Neurosci. 2018;12:259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919950</ArticleId><ArticleId IdType="pubmed">29731706</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens CH, Guthrie NJ, van Roijen M, Halliday GM, Ooi L. Increased tau phosphorylation in motor neurons from clinically pure sporadic amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol. 2019;78:605&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967836</ArticleId><ArticleId IdType="pubmed">31131395</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, McMillan CT, Boller A, Powers J, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:442&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:1072&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25453560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, Zaganas I, et al. Cerebrospinal fluid TAR DNA&#x2010;binding protein 43 combined with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement Geriatr Cogn Disord. 2017;44:144&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28848086</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Spotorno N, Schreiber F, Acosta&#x2010;Cabronero J, Kaufmann J, Machts J, et al. Significance of CSF NfL and tau in ALS. J Neurol. 2018;265:2633&#x2013;45. 10.1007/s00415-018-9043-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9043-0</ArticleId><ArticleId IdType="pubmed">30187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP. Lost in transportation: nucleocytoplasmic transport defects in als and other neurodegenerative diseases. Neuron. 2017;96:285&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozziello T, Bordt EA, Mills AN, Kim SE, Sapp E, Devlin BA, et al. Targeting tau mitigates mitochondrial fragmentation and oxidative stress in amyotrophic lateral sclerosis. Mol Neurobiol. 2021. 10.1101/2021.03.22.436505</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.22.436505</ArticleId><ArticleId IdType="pubmed">34757590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lister JP, Blatt GJ, DeBassio WA, Kemper TL, Tonkiss J, Galler JR, et al. Effect of prenatal protein malnutrition on numbers of neurons in the principal cell layers of the adult rat hippocampal formation. Hippocampus. 2005;15:393&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">15669101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller KA, Glajch KE, Huizenga MN, Wilson RA, Granucci EJ, Dios AM, et al. Hippo signaling pathway dysregulation in human huntington's disease brain and neuronal stem cells. Sci Rep. 2018;8:11355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6063913</ArticleId><ArticleId IdType="pubmed">30054496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H&#x2010;C, Serrano&#x2010;Pozo A, Hashimoto T, Frosch MP, Spires&#x2010;Jones TL, Hyman BT, et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin&#x2010;proteasome system. Am J Pathol. 2012;181:1426&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozziello T, Mills AN, Vaine CA, Penney EB, Fernandez&#x2010;Cerado C, Legarda GPA, et al. Neuroinflammation and histone H3 citrullination are increased in X&#x2010;linked Dystonia Parkinsonism post&#x2010;mortem prefrontal cortex. Neurobiol Dis. 2020;144:105032.</Citation><ArticleIdList><ArticleId IdType="pubmed">32739252</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozziello T, Mills AN, Farhan SMK, Mueller KA, Granucci EJ, Glajch KE, et al. Lipocalin&#x2010;2 is increased in amyotrophic lateral sclerosis. Muscle Nerve. 2020;62:272&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">32369618</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, Howrigan DP, Abbott LE, Klim JR, Topp SD, Byrnes AE, et al. Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat&#x2010;shock protein. Nat Neurosci. 2019;22:1966&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="pubmed">31768050</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Spek RAA, van Rheenen W, Pulit SL, Kenna KP, van den Berg LH, Veldink JH, et al. The project MinE databrowser: bringing large&#x2010;scale whole&#x2010;genome sequencing in ALS to researchers and the public. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:432&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893599</ArticleId><ArticleId IdType="pubmed">31280677</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf&#xf6;ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Ota S, Tanaka K, Ito Y, Hasegawa M, Umeda Y, et al. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol. 2003;53:133&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, Ferrer I, Lezcano E, Forcadas MI, Eizaguirre B, Atares B, et al. A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. Neurology. 2005;64:1578&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883319</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32333900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019;51:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509326</ArticleId><ArticleId IdType="pubmed">31073121</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S, Atkin JD. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res. 2016;1648:633&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">27064076</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Groen EJN, Koppers M, van den Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Murray ME, Rutherford NJ, Castanedes&#x2010;Casey M, DeJesus&#x2010;Hernandez M, Liesinger AM, et al. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol. 2013;125(2):289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Donison NS, Volkening K. Alterations in tau metabolism in ALS and ALS&#x2010;FTSD. Front Neurol. 2020;11:598907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719764</ArticleId><ArticleId IdType="pubmed">33329356</ArticleId></ArticleIdList></Reference><Reference><Citation>He H, Huang W, Wang R, Lin Y, Guo Y, Deng J, et al. Amyotrophic lateral sclerosis&#x2010;associated GGGGCC repeat expansion promotes tau phosphorylation and toxicity. Neurobiol Dis. 2019;130:104493.</Citation><ArticleIdList><ArticleId IdType="pubmed">31176718</ArticleId></ArticleIdList></Reference><Reference><Citation>King A, Al&#x2010;Sarraj S, Troakes C, Smith BN, Maekawa S, Iovino M, et al. Mixed tau, TDP&#x2010;43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and pAla239Thr MAPT (tau) variant. Acta Neuropathol. 2013;125(2):303&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">23053136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly CV, Koenig L, Christensen J, Gordon B, Beaumont H, Dahiya S, et al. Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. Eur J Neurol. 2019;26(9):1235&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6684398</ArticleId><ArticleId IdType="pubmed">30790403</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoji M. Cerebrospinal fluid and plasma tau as a biomarker for brain tauopathy. Adv Exp Med Biol. 2019;1184:393&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">32096052</ArticleId></ArticleIdList></Reference><Reference><Citation>Schraen&#x2010;Maschke S, Sergeant N, Dhaenens C&#x2010;M, Bombois S, Deramecourt V, Caillet&#x2010;Boudin M&#x2010;L, et al. Tau as a biomarker of neurodegenerative diseases. Biomark Med. 2008;2:363&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993973</ArticleId><ArticleId IdType="pubmed">20477391</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A, D&#x2019;Errico E, Introna A, Fraddosio A, Distaso E, Tempesta I, et al. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol. 2018;265:2353&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, Hergesheimer RC, Bakkouche SE, Beltran S, Vourc'h P, Andres CR, et al. Abeta1&#x2010;42 and tau as potential biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis. Int J Mol Sci. 2020;21:2911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7216266</ArticleId><ArticleId IdType="pubmed">32326346</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu&#x2010;Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti&#x2010;Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937795</ArticleId><ArticleId IdType="pubmed">31892365</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16:257&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>He HJ, Wang XS, Pan RM, Wang DL, Liu MN, He RQ. The proline&#x2010;rich domain of tau plays a role in interactions with actin. BMC Cell Biology 2009;10:81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784441</ArticleId><ArticleId IdType="pubmed">19895707</ArticleId></ArticleIdList></Reference><Reference><Citation>McKibben KM, Rhoades E. Independent tubulin binding and polymerization by the proline&#x2010;rich region of tau is regulated by tau&#x2019;s N&#x2010;terminal domain. J Biol Chem. 2019;294(50):19381&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6916478</ArticleId><ArticleId IdType="pubmed">31699899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaan NM, Hamel C, Grabinski T, Combs B. Liquid&#x2010;liquid phase separation induces pathogenic tau conformations in vitro. Nat Commun. 2020;11(1):2809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272632</ArticleId><ArticleId IdType="pubmed">32499559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Vigers M, McCarty J, Rauch JN, Fredrickson GH, Wilson MZ, et al. The proline&#x2010;rich domain promotes tau liquid&#x2010;liquid phase separation in cells. J Cell Biol. 2020;219(11):e202006054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594490</ArticleId><ArticleId IdType="pubmed">32997736</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Inami H, Oiwa K, Murata Y, Sakai S, Komine O, et al. Aggresome formation and liquid&#x2010;liquid phase separation independently induce cytoplasmic aggregation of TAR DNA&#x2010;binding protein 43. Cell Death Dis. 2020;11(10):909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585435</ArticleId><ArticleId IdType="pubmed">33097688</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakravan D, Michiels E, Bratek&#x2010;Skicki A, De Decker M, Van Lindt J, Alsteens D, et al. Liquid&#x2010;liquid phase separation enhances TDP&#x2010;43 LCD aggregation but delays seeded aggregation. Biomolecules. 2021;11(4):548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8068378</ArticleId><ArticleId IdType="pubmed">33917983</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>